HBV/HDV 合并感染：治疗的挑战。
HBV/HDV Coinfection: A Challenge for Therapeutics.
机构信息
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Building 10, Room 9B-16, MSC 1800, Bethesda, MD 20892, USA.
Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, CRC, Room 4-5722, Bethesda, MD 20892, USA.
出版信息
Clin Liver Dis. 2019 Aug;23(3):557-572. doi: 10.1016/j.cld.2019.04.005. Epub 2019 May 24.
Chronic hepatitis D (CHD) results from an infection with the hepatitis B virus and hepatitis D virus (HDV). CHD is the most severe form of human viral hepatitis. Current treatment options consist of interferon alfa, which is effective only in a minority of patients. Study of HDV molecular virology has resulted in new approaches entering clinical trials, with phase-3 studies the most advanced. These include the entry inhibitor bulevirtide, the nucleic acid polymer REP 2139-Ca, the farnesyltransferase inhibitor lonafarnib, and pegylated interferon lambda. This article summarizes the available data on these emerging therapeutics.
慢性乙型肝炎（CHD）是由乙型肝炎病毒和乙型肝炎病毒（HDV）感染引起的。CHD 是人类病毒性肝炎中最严重的一种。目前的治疗方案包括干扰素 alfa，但仅对少数患者有效。对 HDV 分子病毒学的研究产生了新的治疗方法，目前最先进的是 3 期临床试验。这些方法包括进入抑制剂 bulevirtide、核酸聚合物 REP 2139-Ca、法尼酯转移酶抑制剂 lonafarnib 和聚乙二醇干扰素 lambda。本文总结了这些新出现的治疗方法的现有数据。
Zotero 插件